Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar 31;20(4):5667-79.
doi: 10.3390/molecules20045667.

Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis

Simone Carradori  1 , Adriano Mollica  2 , Celeste De Monte  3 , Arianna Ganese  4 , Claudiu T Supuran  5
Affiliations
Review

Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis

Simone Carradori et al. Molecules. .

Abstract

Due to the recognized biological role of nitric oxide (NO) donating derivatives and of selective inhibitors of specific human carbonic anhydrase isoforms (CA, EC 4.2.1.1), promising compounds having an aromatic/heterocyclic primary sulfonamide and functionalized with NO-releasing moieties have been designed. These bifunctional agents have been tested in vitro and in vivo to assess their dual pharmacological activity. According to the encouraging results they could be proposed for the treatment of angle-open glaucoma, cancer regression and osteoporosis, in which both NO and CA activities are involved.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Diseases in which NO-donors and selective hCA inhibitors as dual pharmacological agents are involved.
See this image and copyright information in PMC

References

    1. Morphy R., Kay C., Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov. Today. 2004;9:641–651. doi: 10.1016/S1359-6446(04)03163-0. - DOI - PubMed
    1. Miller M.R., Megson I.L. Recent developments in nitric oxide donor drugs. Br. J. Pharmacol. 2007;151:305–321. doi: 10.1038/sj.bjp.0707224. - DOI - PMC - PubMed
    1. Schmidt H.H.H.W., Walter U. NO at Work. Cell. 1994;78:919–925. doi: 10.1016/0092-8674(94)90267-4. - DOI - PubMed
    1. Gasco A., Fruttero R., Rolando B. Focus on recent approaches for the development of new NO-donors. Mini-Rev. Med. Chem. 2005;5:217–229. doi: 10.2174/1389557053402684. - DOI - PubMed
    1. Serafim R.A.M., Primi M.C., Trossini G.H.G., Ferreira E.I. Nitric oxide: State of the art in drug design. Curr. Med. Chem. 2012;19:386–405. doi: 10.2174/092986712803414321. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources